The Moli-sani Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03242109 |
Recruitment Status :
Completed
First Posted : August 8, 2017
Last Update Posted : August 8, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Cardiovascular disease and malignancies account for more than 70% of all causes of mortality and morbidity in Italy. There is a subtle balance between genetic determinants and lifestyle, that often defines the line between health and sickness. So far studies aiming at identifying risk factors have mainly come from Northern Europe and the USA. It was to understand this balance between genetics and environmental determinants better, and to tailor appropriate preventive strategies for Italian and other Southern European populations, that the Moli-sani study was launched, transforming a small Italian region into a large scientific laboratory: the "Molise lab".
Each participant received a thorough medical check-up at no cost to either him/her or the national health service, resulting in thousands of hours of free public health care. With a completely computerized system, Moli-sani is a "paperless" study, in which researchers and participants communicate using recently developed technologies such as mobile phone text messages (SMS). The biological data bank (the "MoliBank") is one of the largest in Europe. Paying particular attention towards innovation and new technologies, the Moli-sani study has placed itself at the cutting edge of a new paradigm crossing research and prevention
Condition or disease |
---|
Cardiovascular Diseases Cardiovascular Risk Factor Cancer Neurodegenerative Diseases Diabetes Pulmonary Disease |
Study Type : | Observational |
Actual Enrollment : | 24325 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | An Epidemiological Study of Risk Factors for Cardiovascular Disease and Tumors in an Adult Population of the Molise Region |
Actual Study Start Date : | March 1, 2005 |
Actual Primary Completion Date : | April 30, 2010 |
Actual Study Completion Date : | April 30, 2010 |
- Primary cardiovascular diseases [ Time Frame: 10 years ]Primary fatal and nonfatal incident cases of CHD (unstable angina, myocardial infarction, coronary revascularization and sudden death for unspecified cardiac event) and cerebrovascular disease that occurred in the cohort during follow-up
- Cancer [ Time Frame: 10 years ]Primary fatal and nonfatal incident cases of cancer that occurred in the cohort during follow-up, assessed by cross-linkage with hospital discharge record and regional death registry
- Heart failure [ Time Frame: 10 years ]Primary fatal and nonfatal incident cases of heart failure that occurred in the cohort during follow-up, assessed by cross-linkage with hospital discharge record and regional death registry
- Atrial fibrillation [ Time Frame: 10 years ]Primary fatal and nonfatal incident cases of atrial fibrillation that occurred in the cohort during follow-up, assessed by cross-linkage with hospital discharge record and regional death registry
- Diabetes [ Time Frame: 10 years ]Primary incident cases of diabetes that occurred in the cohort during follow-up, assessed by cross-linkage with hospital discharge record and regional death registry or pharmacological prescription registry. Diabetes onset is defined as blood glucose ≥126 mg/dl or by use of specific pharmacological treatment
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 35 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Resident in the Molise region (Italy), aged >35.
Exclusion Criteria:
- pregnancy at the time of recruitment, disturbances in understanding or willingness, current poly-traumas or coma, refusal to sign the Informed Consent form.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03242109
Italy | |
Irccs Neuromed | |
Pozzilli, Italy, 86067 |
Principal Investigator: | Licia Iacoviello, MD, PhD | Department of Epidemiology and Prevention, IRCCS Neuromed |
Responsible Party: | Licia Iacoviello, MD, PhD, Neuromed IRCCS |
ClinicalTrials.gov Identifier: | NCT03242109 |
Other Study ID Numbers: |
50/17 |
First Posted: | August 8, 2017 Key Record Dates |
Last Update Posted: | August 8, 2017 |
Last Verified: | July 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | sumbmission of a research proposal form to be approved by the Moli-sani scientific committee and signature of a research agreement. |
Supporting Materials: |
Study Protocol Informed Consent Form (ICF) Clinical Study Report (CSR) |
Time Frame: | Upon request |
Access Criteria: | Approval by the Moli-sani study Scientific committee |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Neurodegenerative Diseases Cardiovascular Diseases Nervous System Diseases |